Protein and lipid oxidative damage in streptozotocin-induced diabetic rats submitted to forced swimming test: the insulin and clonazepam effect.
Diabetes may modify central nervous system functions and is associated with moderate cognitive deficits and changes in the brain, a condition that may be referred to as diabetic encephalopathy. The prevalence of depression in diabetic patients is higher than in the general population, and clonazepam is being used to treat this complication. Oxidative stress may play a role in the development of diabetes complications. We investigated oxidative stress parameters in streptozotocin-induced diabetic rats submitted to forced swimming test (STZ) and evaluated the effect of insulin (STZ-INS) and/or clonazepam (STZ-CNZ and STZ-INS-CNZ) acute treatment on these animal model. Oxidative damage to proteins measured as carbonyl content in plasma was significantly increased in STZ group compared to STZ treated groups. Malondialdehyde plasma levels were significantly reduced in STZ-INS and STZ-INS-CNZ groups when compared to STZ rats, being significantly reduced in STZ-INS-CNZ than STZ-INS rats. The activities of the antioxidant enzymes catalase, superoxide dismutase and glutathione peroxidase showed no significant differences among all groups of animals. These findings showed that protein and lipid damage occurs in this diabetes/depression animal model and that the associated treatment of insulin and clonazepam is capable to protect against oxidative damage in this experimental model.
Wayhs
Carlos Alberto Yasin
CA
Programa de Pós-Graduação em Ciências Farmacêuticas, Porto Alegre, RS, Brazil. manowayhs@yahoo.com.br
Manfredini
Vanusa
V
Sitta
Angela
A
Deon
Marion
M
Ribas
Graziela
G
Vanzin
Camila
C
Biancini
Giovana
G
Ferri
Marcelo
M
Nin
Maurício
M
Barros
Helena Maria Tannhauser
HM
Vargas
Carmen Regla
CR
D000818:Animals; D002998:Clonazepam / Q000494:pharmacology* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D048909:Diabetes Complications / Q000378:metabolism*; D004195:Disease Models, Animal; D018757:GABA Modulators / Q000494:pharmacology / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D013315:Stress, Psychological / Q000150:complications / Q000378:metabolism; D013550:Swimming / Q000523:psychology
D018757:GABA Modulators; D007004:Hypoglycemic Agents; D007328:Insulin; D002998:Clonazepam